CemiplimAb-Rwlc Survivorship and Epidemiology (CASE): A Prospective Study of the Safety and Efficacy of Cemiplimab in Patients With Advanced Cutaneous Squamous Cell Carcinoma (CSCC) in a Real-World Setting. J of Skin 2023, 7 (2), s174. https://doi.org/10.25251/skin.7.supp.174.